Home Featured Page 74

Featured

Latest

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates

PT464 – Bodywork, Somatic Literacy, and Understanding Trauma: The Mind and...

Psychedelica Europa: A Deep Dive Into the Latest Psychedelic Research, Regulations...

Pα+ Psychedelic Patent Analysis (October 2023)

PT463 – Bringing Intention, Ceremony, and Inner Healing Intelligence to Modern...

Explore Kanna: A Legal Psychoactive Plant Ally in Turbulent Times

PT462 – Touch Therapy, Wearable Technology, and Treating Trauma with Safety

Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the...

Pα+ Mini Interview with Eddie Jacobs: Post-Trial Provisions in Clinical Psychedelic...

Pα+ Psychedelic Bulletin #149: Worldwide Psychedelic Policy Developments

EDITOR PICKS

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.